They can have the anti-coagulation drugs, which are called anti-apixaban and vitamin K (AVK), a positive effect on the cognitive function of the patient, is also the research published today in the European Heart Journal.
Atrial fibrillation, a condition that causes irregular heartbeats, affects people of all ages and increases the risk of premature death from heart failure and leads to one of three strokes.
Special equipment can treat atrial fibrillation by stopping irregular electrical signals in the heart that cause symptoms through a procedure known as a catheteromy.
In this procedure, the electrical world uses a long, interconnected wire in the heart through the thigh to connect a high frequency current. This heats the inner surface of the heart where irregular electrical signals are produced, creating scar tissue, thus preventing incorrect impulses.
Patients with atrial fibrillation are at risk of stroke in the hours and days after the procedure. Therefore, they require anticoagulants to block blood and prevent blood clots.
To determine the optimal treatment of anticoagulants for patients undergoing catheter eradication, the German network carried out for atrial fibrillation (AFNET) in collaboration with the German Cardiovascular Research Center (DZHK) experience AXAFA – AFNET 5 comparing Apixban and AVK. In a randomized trial, 633 patients in Europe and the United States received continuous Apixaban or VKA before and after catheter eradication.
Professor Paulus Kirchhoff, from the Cardiovascular Institute’s Science Institute at the University of Birmingham, to major international researchers in clinical trials and the head of AFNET: “used for catheter distillation is increasingly used to treat patients with atrial fibrillation, but This procedure leaves patients at risk of stroke. Hemorrhagic and severe brain injuries, we also know that thrombotic events can affect cognitive function.
“We found that the bleeding rate was half of what we expected and there was a significant reduction in the incidence of stroke, noting only two events in the experiment.
“In addition, the seven episodes of heart plugs – two with Opeixaban and five with AVK management – with the exchange, without the need for anti-poisoning”
Using the Montreal Cognitive Knowledge Test, the researchers found a small but statistically significant improvement in cognitive function in both groups at the end of the study.
Another unique feature of the experiment was the use of magnetic resonance imaging (MRI) images in more than half of the patients in the study within 48 hours after ablation to determine acute brain injuries related to the brain. Magnetic resonance imaging (MRI) results showed no difference in clinically silent acute brain injuries between the treatment arms.
Professor Kirchhoff said that the results of the experiment will have a significant impact on the treatment: “The results of this experiment will go a long way towards reassuring doctors that the continuation of apixaban is a safe and effective alternative to VKAs for patients who are subject to the eradication of atrial fibrillation, even those at risk of stroke. ”
Professor Kirchoff presents a summary of these findings today (March 20) at the Conference of the European Society of Cardiology in Barcelona, Spain.